Elan could receive drug royalty payments

DUBLIN-based pharmaceutical company Elan could start benefiting from royalty payments from a new drug being developed by Johnson & Johnson as soon as next year.

Johnson & Johnson’s injection treatment for patients with schizophrenia — Paliperidone Palmitate — was lodged as a new drug application to the Food and Drug Administration (FDA) in the US last October.

The FDA is expected to give the green light for the commercialisation of the treatment later this year.